A “far superior” bird flu jab has been developed in Britain using AI technology.
Cambridge University scientists employed state of the art artificial intelligence to create the vaccine that outperforms current stockpiled bird flu jabs.
It is a third success for the Cambridge team using their AI-guided technique for designing vaccines against potentially deadly highly infectious viruses.
The new bird flu vaccine gave complete protection against globally circulating, diverse variants of the disease in animal trials.
The study, published in the journal Cell Reports Medicine, found the vaccine is “far superior” to bird flu vaccines currently stockpiled by several governments for use in the event of a human outbreak.
Those vaccines were found to protect only around 50% of animals exposed to multiple bird flu variants, compared with complete protection achieved by the new Cambridge vaccine.
Developed by the University of Cambridge and spin-out firm DIOSynVax Ltd, it is the latest in a series of vaccines made in an entirely new way.
Their active ingredient is designed to give lasting protection from thousands of virus variants in a single jab.
The study proves that the team’s “plug and play” approach can be used to create safe, highly effective vaccines for a plethora of infectious diseases threatening animal and human health.

Study leader Professor Jonathan Heeney said: “Rather than providing immunity to a single variant of bird flu, our new broad-spectrum vaccine is protective against a huge range of variants.
“It’s designed to anticipate viral evolution, rather than reacting to it “
Bird flu is spreading in animals around the world and is currently considered a “significant” threat to global public health.
Variants in south-east Asia have caused severe disease and high death rates in humans.
Like the coronaviruses that caused Covid-19, and other emerging infectious diseases, bird flu is an RNA virus.
Prof Heeney says RNA viruses represent a particular threat to human health because they can mutate rapidly into new strains that can jump from animals to humans and evade our immune systems – and existing vaccines.
Earlier this year the team announced that their broad-spectrum coronavirus vaccine had proved safe in human trials, and published results showing their broad-spectrum flu vaccine protects against both human and swine flu viruses.
Current pandemic preparedness relies on stockpiling vaccines against individual virus variants that have already emerged.
The Cambridge team’s approach uses AI-guided engineering to create broadly protective vaccines intended to remain effective across a wide range of existing and future variants.
Prof Heeney said: “These new-generation vaccines are a game changer for national biosecurity and more resilient public health.
“They mean we can be prepared to respond immediately to virus epidemics and pandemics, rather than the current scenario of always being on the back foot and responding with a strain which will have changed.”
He explained that the active ingredient in a vaccine, called an antigen, triggers the body’s immune system to produce a protective response.
That trains the body to fight off future infection by a pathogen containing this specific antigen.

How scientists used AI to design a vaccine against multiple strains
To design the bird flu vaccine, the team collected the genetic sequence data of all the bird flu viruses logged by surveillance programmes around the world, which take virus samples from wildlife, livestock and humans infected with bird flu.
The team built an AI tool to integrate the huge amount of genetic data and use it to design a range of “super-antigens” which contain the antigen features common to the whole group of viruses.
These were screened in cells to select the best one for the vaccine, which was then tested in animal trials.
Prof Heeney said: “Using AI vastly speeds up the process of vaccine design, and then we can test the vaccine candidates in the lab to make sure they’re robust and safe.”
He says the new class of universal vaccines is “future-proofed” – they not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans.
New bird flu vaccine outperforms existing jabs in animal trials
In the new study, the DIOSynVax vaccine completely protected mice and ferrets against a range of genetically distinct variants of the virus causing bird flu – all of which have caused human infections and represent potential pandemic threats.
In comparison, only half the animals survived the same viruses when immunised with the World Health Organisation’s (WHO) existing bird flu vaccine.
The bird flu vaccine stockpiled by governments is based on representative virus isolates identified through the WHO’s pandemic influenza preparedness programme.
It was designed to protect against one specific strain of the disease, but the study found it provides “minimal” protection against other strains in circulation.
Traditional vaccines are designed to give protection to specific virus strains or variants that have already been detected in humans.
But since viruses are constantly mutating, by the time the vaccines are manufactured and distributed, they have limited protection and must be updated regularly to try and keep up.
Researchers hope to begin human trials of new bird flu vaccine
Prof Heeney says the next step is to test the new bird flu vaccine in human clinical trials, so that it can be ready to be given to humans immediately, when needed.
He added: “It’s when bird flu adapts to live in the airways of mammals that we start to get really nervous, not only because of the impact on animal health but because of the threat to humans.
“If we can make better animal vaccines, then we can better protect human health as well.”
The team’s goal is to create broadly protective vaccines for both animals and humans, helping reduce opportunities for pathogens to emerge, adapt and spread.
The team received £4.28 million last month from UK Research and Innovation (UKRI) and Defra as part of a national biosecurity investment aimed at tackling future disease outbreaks.
The researchers are also working on a seasonal flu vaccine that would provide protection over several flu seasons.
Preliminary results show that the vaccine antigen they designed in 2018 is still effective after seven years.


































